These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 5631729

  • 1. [Iron storage disease].
    Heilmeyer L.
    Munch Med Wochenschr; 1967 Mar 31; 109(13):677-84. PubMed ID: 5631729
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Diseases caused by iron metabolism disorders and their therapy].
    Stacher A.
    Wien Z Inn Med; 1969 Mar 31; 50(3):89-105. PubMed ID: 4903041
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C, La Nasa G, Contu L, Galimberti M, Polchi P, Angelucci E, Baronciani D, Barbanti I, Muretto P, Lucarelli G.
    Bone Marrow Transplant; 1993 Mar 31; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract] [Full Text] [Related]

  • 7. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
    Giraud P, Orsini A, Giraud F, Pinsard N.
    Arch Fr Pediatr; 1965 Apr 31; 22(4):463-8. PubMed ID: 5826583
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of iron storage disorders.
    Halliday JW, Bassett ML.
    Drugs; 1980 Sep 31; 20(3):207-15. PubMed ID: 7428669
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Physiopathology and classification of hemochromatosis].
    Bourel M, Simon M, de Nercy YH, Brissot P, Hespel JP.
    Rev Prat; 1977 Feb 01; 27(7):339-50. PubMed ID: 322245
    [No Abstract] [Full Text] [Related]

  • 12. [Present aspects of the treatment of hemochromatosis (apropos of 100 observations)].
    Darnis F, Mossé A, Breauté C, Delorme ML.
    Ann Med Interne (Paris); 1971 Dec 01; 122(12):1193-210. PubMed ID: 5151624
    [No Abstract] [Full Text] [Related]

  • 13. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
    Nijjar PS, Vongooru H, Tamene A, Valeti U, Masri C.
    Minn Med; 2015 Jul 01; 98(7):47. PubMed ID: 26267924
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neonatal hemochromatosis: failure of deferoxamine therapy.
    Jonas MM, Kaweblum YA, Fojaco R.
    J Pediatr Gastroenterol Nutr; 1987 Jul 01; 6(6):984-8. PubMed ID: 3681586
    [Abstract] [Full Text] [Related]

  • 16. Treatment of iron overload.
    Cohen A, Witzleben C, Schwartz E.
    Semin Liver Dis; 1984 Aug 01; 4(3):228-38. PubMed ID: 6091277
    [No Abstract] [Full Text] [Related]

  • 17. The pathology of the liver in hemochromatosis.
    Powell LW, Kerr JF.
    Pathobiol Annu; 1975 Aug 01; 5():317-37. PubMed ID: 1196674
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Management of iron overload with a disposable multi-day delivery system.
    Paolo C, Francesco S, Sergio A.
    Am J Hematol; 1996 Jan 01; 51(1):95. PubMed ID: 8571948
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.